• European Commission Approves Gazyvaro as First-Line Follicular Lymphoma Therapy
  • Radioactive Iodine Increases Risk of Thyroid Cancer Patient Developing Acute Myeloid Leukemia, Study Reports
  • NCI Renews $12.4 Million Grant to University of Iowa, Mayo Clinic for Lymphoma Research
  • NCI Grants $1.5M for Phase 3 Trial of SGX301 for Cutaneous T-cell Lymphoma
  • Biosimilar GP2013 Is Equivalent to Rituxan as Lymphoma Therapy, Phase 3 Trial Shows
  • UCSD Researchers Awarded $18.3M to Study New Combo Therapy for B-cell Cancers
  • Bayer Presents Copanlisib Combination Trials at Scientific Meeting
  • FDA Approves Bayer’s Aliqopa for Relapsed Follicular Lymphoma
  • Jazz Partners with ImmunoGen to Develop Antibody-Drug Conjugate for AML, Other Blood Diseases
  • Study Identifies Factors Associated with Young Cancer Survivors’ Reduced Ability to Work
  • Transplant Recipients Account for 3% of non-Hodgkin Lymphoma Cases in Children, Study Finds
  • Advisory Agency Decision Will Make Lymphoma Therapy Adcetris More Accessible in UK